A 68-year-old man is evaluated in the clinic for a 4-week history of worsening fatigue, un… — USMLE Step 3

A 68-year-old man is evaluated in the clinic for a 4-week history of worsening fatigue, unintentional weight loss of $4\text{ kg}$ ( $8.8\text{ lb}$ ), and frequent palpitations. He has a history of ischemic cardiomyopathy with a left ventricular ejection fraction of $30\%$ and an implanted cardioverter-defibrillator (ICD) placed for secondary prevention of sustained ventricular tachycardia. His medications include amiodarone, which was started 2 years ago for frequent ICD shocks, as well as carvedilol, lisinopril, empagliflozin, and furosemide. Vital signs show a blood pressure of $130/80\text{ mmHg}$ and a heart rate of $95/\text{min}$ . Physical examination reveals a fine resting tremor. The thyroid gland is normal in size, non-tender, and without palpable nodules. There is no exophthalmos. Laboratory studies reveal:

Laboratory Test	Result	Reference Range
Thyroid-stimulating hormone (TSH)	$0.01\text{ }\mu\text{U/mL}$	$0.4-4.0\text{ }\mu\text{U/mL}$
Free T4	$3.2\text{ ng/dL}$	$0.8-1.8\text{ ng/dL}$
Free T3	$6.1\text{ pg/mL}$	$2.3-4.2\text{ pg/mL}$

Which of the following is the most appropriate next step in the evaluation of this patient's condition to guide pharmacological management?

Color flow Doppler ultrasonography of the thyroidCevap
B
Radioactive iodine uptake scan
C
Empiric initiation of methimazole
D
Immediate discontinuation of amiodarone
E
Measurement of thyroid-stimulating immunoglobulin

Cevap

The correct next step is to perform color flow Doppler ultrasonography of the thyroid to differentiate the subtype of amiodarone-induced thyrotoxicosis.

Amiodarone-induced thyrotoxicosis (AIT) presents a unique monitoring and management challenge due to the drug's high iodine content and long half-life. AIT is divided into Type 1 (hyperthyroidism due to the Jod-Basedow effect in a patient with underlying thyroid pathology) and Type 2 (destructive thyroiditis). Determining the correct subtype is strictly required before initiating therapy, as the treatments differ drastically: Type 1 requires thionamides (e.g., methimazole) to block hormone synthesis, whereas Type 2 requires glucocorticoids (e.g., prednisone) to reduce inflammation. Color flow Doppler ultrasonography is the diagnostic test of choice to differentiate the two; it demonstrates increased vascularity in Type 1 and decreased or absent vascularity in Type 2.

Adım Adım Çözüm

Identify the primary clinical problem.

The patient has low TSH and elevated Free T4/T3 while taking amiodarone, confirming Amiodarone-Induced Thyrotoxicosis (AIT).

Amiodarone contains high amounts of iodine and can cause severe thyroid dysfunction.

Determine the diagnostic requirements for AIT management.

AIT must be classified as Type 1 (increased hormone synthesis due to underlying thyroid disease) or Type 2 (destructive thyroiditis) because the treatments are entirely different (methimazole for Type 1, glucocorticoids for Type 2).

Treating the wrong subtype leads to therapeutic failure and prolonged thyrotoxicosis.

Select the appropriate modality to differentiate AIT subtypes.

Color flow Doppler ultrasonography is chosen. It shows increased vascularity in Type 1 AIT and decreased or absent vascularity in Type 2 AIT.

Standard hyperthyroidism evaluations like Radioactive Iodine Uptake (RAIU) scans are ineffective here because amiodarone's iodine load saturates the gland, resulting in universally low uptake regardless of the AIT subtype.

Anahtar Kavram

Patients with Amiodarone-Induced Thyrotoxicosis (AIT) require color flow Doppler ultrasonography to differentiate between Type 1 (treated with thionamides) and Type 2 (treated with glucocorticoids) because standard radioactive iodine scans are invalidated by amiodarone's iodine load.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru